
The Real Story of KRAS Drugs in Pancreatic Cancer Treatment
KRAS pancreatic cancer treatment just reached a turning point: drugs targeting the gene behind 90% of these tumors are now showing real benefit in trials.

KRAS pancreatic cancer treatment just reached a turning point: drugs targeting the gene behind 90% of these tumors are now showing real benefit in trials.

Pancreatic cancer chemo side effects vary by regimen—and fatigue affects over 80% of people on chemo. Here's what's common, what's serious, and what helps.

FOLFIRINOX vs. gemcitabine isn't simply 'stronger wins'—the four-drug regimen works better but hits harder, and fitness decides which your team picks.

Whipple procedure recovery is demanding but well-charted — and where you have surgery matters: high-volume centers report far lower complication rates.

Pancreatic cancer treatment is chosen by stage and whether surgery is possible—from the Whipple procedure to chemo regimens like FOLFIRINOX and NALIRIFOX.

End-stage pancreatic cancer means the disease has spread beyond the pancreas. Here's what symptoms, the final days, and hospice support really look like.

How fast pancreatic cancer grows surprises people: genomic studies trace ~15 silent years before it can spread—which is why it's so often caught late.

Resectable or unresectable pancreatic cancer isn't about spread alone—it's whether the tumor encases key vessels. Only 15–20% are operable.

Heat exhaustion and heat stroke can look alike in the first minutes — but one becomes a life-threatening emergency.

Stage 4 pancreatic cancer life expectancy is sobering, but the numbers are averages, not your future — and new RAS-targeted drugs are shifting it.